LIVIVO - Search results -

Search results

Result 1 - 10 of total 493

Search options

Book ; Online ; E-Book: Ovarian cancers

Pujade-Lauraine, Éric / Ray-Coquard, Isabelle / Lécuru, Fabrice

advances through international research cooperation (GINECO, ENGOT, GCIG)

2017

Author's details	Eric Pujade-Lauraine, Isabelle Ray-Coquard, Fabrice Lécuru editors
Keywords	Eierstockkrebs
Subject	Ovarialkarzinom ; Ovarialcarcinom ; Ovarialkrebs
Language	English
Size	1 Online Ressource (ix, 286 Seiten)
Publisher	Springer
Publishing place	Cham
Publishing country	Switzerland
Document type	Book ; Online ; E-Book
Remark	Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
HBZ-ID	HT019442257
ISBN	978-3-319-32110-3 ; 9783319321080 ; 3-319-32110-2 ; 3319321080
DOI	10.1007/978-3-319-32110-3
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Driving forward: beneficial treatment strategies for leiomyosarcoma patients.

Ray-Coquard, Isabelle

Future oncology (London, England)

2022 Volume 18, Issue 29s, Page(s) 1–2

Abstract: Tweetable abstract "Leiomyosarcomas, as a group, represent one of the most common subtypes of soft tissue sarcoma, accounting for 10-20% of all cases." ...

Abstract	Tweetable abstract "Leiomyosarcomas, as a group, represent one of the most common subtypes of soft tissue sarcoma, accounting for 10-20% of all cases."
MeSH term(s)	Humans ; Leiomyosarcoma/drug therapy ; Sarcoma/drug therapy ; Soft Tissue Neoplasms
Language	English
Publishing date	2022-09-26
Publishing country	England
Document type	Journal Article
ZDB-ID	2274956-1
ISSN	1744-8301 ; 1479-6694
ISSN (online)	1744-8301
ISSN	1479-6694
DOI	10.2217/fon-2022-0634
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6478: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients.

Turinetto, Margherita / Meeus, Pierre / Ray-Coquard, Isabelle

Current opinion in oncology

2023 Volume 35, Issue 4, Page(s) 288–291

Abstract: Purpose of review: Currently, the only systemic therapy approved for advanced leiomyosarcoma is Doxorubicin-based monotherapy. Despite disappointing progression-free survival (PFS) and overall survival (OS), no combination therapy has formally ever ... ...

Abstract	Purpose of review: Currently, the only systemic therapy approved for advanced leiomyosarcoma is Doxorubicin-based monotherapy. Despite disappointing progression-free survival (PFS) and overall survival (OS), no combination therapy has formally ever proven to be more effective. In this clinical setting, selecting the most efficient therapy is key, as most patients become quickly symptomatic with poor performance status.This review aims to describe the current emerging role of Doxorubicin and Trabectedin in first-line setting, compared with doxorubicin alone the current standard of treatment. Recent findings: Previous randomized trials focusing on combination therapies (Doxorubicin + ifosfamide, doxorubicin + evofosfamide, doxorubicin + Olaratumab, or Gemcitabine + Docetaxel) never reported positive results on the primary endpoint (OS or PFS). For the first time, the randomized phase III LMS-04 demonstrated that Doxorubicin and Trabectedin have a better PFS and disease control rate (DCR) compared with Doxorubicin, with higher but still manageable toxicities. Summary: In the first-line setting, the results of this trial were pivotal for numerous reasons; Doxorubicin-Trabectedin is the first combination that has been proven to be more effective in terms of PFS, ORR and trend of OS compared with doxorubicin alone; moreover, it is clear that trials regarding soft tissue sarcoma should strive to be histology-driven.
MeSH term(s)	Humans ; Trabectedin/therapeutic use ; Leiomyosarcoma/drug therapy ; Doxorubicin ; Sarcoma/drug therapy ; Soft Tissue Neoplasms/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Chemical Substances	Trabectedin (ID0YZQ2TCP) ; Doxorubicin (80168379AG)
Language	English
Publishing date	2023-05-18
Publishing country	United States
Document type	Review ; Journal Article
ZDB-ID	1049384-0
ISSN	1531-703X ; 1040-8746
ISSN (online)	1531-703X
ISSN	1040-8746
DOI	10.1097/CCO.0000000000000961
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3046: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book: Les cancers ovariens

Guastalla, Jean-Paul / Ray-Coquard, Isabelle

(Collection oncologie pratique)

2006

Author's details	Jean-Paul Guastalla ; Isabelle Ray-Coquard
Series title	Collection oncologie pratique
Keywords	Ovarian Neoplasms ; Gynecologic Surgical Procedures / methods ; Eierstockkrebs
Subject	Ovarialkarzinom ; Ovarialcarcinom ; Ovarialkrebs
Language	French
Size	550 S. : Ill., graph. Darst., 24 cm
Publisher	Springer
Publishing place	Paris u.a.
Publishing country	France
Document type	Book
Note	Literaturangaben
HBZ-ID	HT015210935
ISBN	978-2-287-25168-9 ; 2-287-25168-5
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2007 A 4510	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Gynecological sarcomas: literature review of 2020.

Hanvic, Brunhilde / Ray-Coquard, Isabelle

Current opinion in oncology

2021 Volume 33, Issue 4, Page(s) 345–350

Abstract: Purpose of review: This article, focus on recently published data of the last 18 months on the management of gynecologic sarcomas.: Recent findings: Different tools have been studied to identify the differences between benign from malignant uterine ... ...

Abstract	Purpose of review: This article, focus on recently published data of the last 18 months on the management of gynecologic sarcomas. Recent findings: Different tools have been studied to identify the differences between benign from malignant uterine conjonctive tumor.Molecular biology impact more and more on the diagnosis of uterine sarcoma with new definitions of very specific groups. This will make it possible to better define the last group of endometrial sarcoma which has been defined as undifferentiated.In several articles, surgical approaches and fertility-sparing surgery were described including the role of surgery for recurrences.Some other articles have evaluated the potential benefice of adjuvant therapy for uterine sarcoma with early stages.Several new targeted therapies are in development. Notably deoxyribonucleic acid repair machinery in uterine leiomyosarcoma and also immune therapies, transforming growth factor beta pathway, mechanistic target of rapamycin inhibitor, anti angiogenics, etc. Summary: This last year the potential interest for uterine sarcoma increased, demonstrated by the increasing number of publications in the literature compared to previous years. Despite this greater interest over time, the standard of care for uterine sarcoma does not change and we are always waiting for new innovative therapies able to change routine practice and survival of patients. Currently, the result of different clinical trials, which include new options as targeted molecular approach or immune checkpoint inhibitors are closed to be reported.
MeSH term(s)	Chemotherapy, Adjuvant ; Endometrial Neoplasms/diagnosis ; Endometrial Neoplasms/therapy ; Female ; Genital Neoplasms, Female/diagnosis ; Genital Neoplasms, Female/therapy ; Gynecologic Surgical Procedures ; Humans ; Leiomyosarcoma/diagnosis ; Leiomyosarcoma/therapy ; Radiotherapy, Adjuvant ; Randomized Controlled Trials as Topic ; Sarcoma/diagnosis ; Sarcoma/therapy ; Sarcoma, Endometrial Stromal/diagnosis ; Sarcoma, Endometrial Stromal/therapy
Language	English
Publishing date	2021-05-03
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1049384-0
ISSN	1531-703X ; 1040-8746
ISSN (online)	1531-703X
ISSN	1040-8746
DOI	10.1097/CCO.0000000000000753
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3046: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: [No title information]

Joly, Florence / Ray-Coquard, Isabelle

Bulletin du cancer

2021 Volume 108, Issue 9S1, Page(s) S1–S4

Abstract: Since the previous 2013 and 2016 recommendations for clinical practice (RPC) Nice/Saint-Paul-de-Vence for gynecological cancers, the management of ovarian cancer has become more complex with the evolution of the quality criteria recommended for surgery ... ...

Title translation	Mise à jour 2021 des recommandations pour la pratique clinique de Nice/Saint-Paul-de-Vence dans le cancer de l’ovaire épithélial de haut grade: Updated 2021 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in epithelial high grade ovarian cancer.
Abstract	Since the previous 2013 and 2016 recommendations for clinical practice (RPC) Nice/Saint-Paul-de-Vence for gynecological cancers, the management of ovarian cancer has become more complex with the evolution of the quality criteria recommended for surgery and the integration of molecular biology for the decision of medical treatments, especially for high grade epithelial ovarian cancers. Surgical indications have become more precise both in the first line and in the context of relapse. Treatments with PARP inhibitors is a major advance in medical management with significant efficacy in maintenance after response to platinum-based chemotherapy. The benefit already known in the case of late relapse has also been demonstrated in first-line treatment with progression-free survival never observed in this pathology with patients with very long responses, especially in the case of BRCA gene abnormalities (somatic or constitutional). In 2021, medical and surgical strategies in front line including PARP inhibitors associated or not with bevacizumab as a maintenance complement after platinum chemotherapy are guided by both response to platinum agents and molecular profiling including BRCA (somatic or constitutional) genetic status and homologous recombination pathway (HRD) abnormalities, that should be early tested. On behalf of the GINECO national oncologist group, we have updated the guidelines for high grade ovarian epithelial cancer (excepted rare tumors) in order to allow rapid dissemination of the latest advances to the medical community and improve daily practice.
MeSH term(s)	Antineoplastic Agents, Immunological/therapeutic use ; Bevacizumab/therapeutic use ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/genetics ; Carcinoma, Ovarian Epithelial/pathology ; Carcinoma, Ovarian Epithelial/surgery ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Humans ; Maintenance Chemotherapy ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/surgery ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/surgery ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Progression-Free Survival
Chemical Substances	Antineoplastic Agents, Immunological ; Poly(ADP-ribose) Polymerase Inhibitors ; Bevacizumab (2S9ZZM9Q9V)
Language	French
Publishing date	2021-12-27
Publishing country	France
Document type	Journal Article ; Practice Guideline
ZDB-ID	213270-9
ISSN	1769-6917 ; 0007-4551
ISSN (online)	1769-6917
ISSN	0007-4551
DOI	10.1016/S0007-4551(21)00581-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.15: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial.

Fabbro, Michel / Lamy, Pierre-Jean / Touraine, Célia / Floquet, Anne / Ray-Coquard, Isabelle / Mollevi, Caroline

Frontiers in oncology

2024 Volume 13, Page(s) 1308630

Abstract: HE4 and CA-125 are used for epithelial ovarian cancer (EOC) screening, diagnosis, and follow-up. Our objective was to study HE4 and CA-125 kinetics in patients treated for recurrent EOC. Serum samples were prospectively collected before the first ... ...

Abstract	HE4 and CA-125 are used for epithelial ovarian cancer (EOC) screening, diagnosis, and follow-up. Our objective was to study HE4 and CA-125 kinetics in patients treated for recurrent EOC. Serum samples were prospectively collected before the first chemotherapy cycle and every 3 months until disease progression. Data from 89/101 patients could be analyzed. At baseline, the median CA-125 and HE4 concentrations were 210 IU/L (7-10,310) and 184 pM (31-4,836). Among the 12 patients (13%) with normal CA-125 (<35 IU/L) concentration, eight had HE4 concentration ≥75 pM, and among the 16 patients with normal HE4 concentration (18%), 12 had increased CA-125 concentration. The median nadir concentrations were 31 IU/L (3-8,744) for CA-125 and 75 pM (20-4,836) for HE4. The median times to nadir were 14 (0-130) weeks for CA-125 and 12 (0-52) weeks for HE4. In multivariate analysis, CA-125 and HE4 nadir concentrations (<35 IU/L, HR 0.35, 95% CI: 0.17-0.72 and<75 pM, HR 0.40, 95% CI: 0.20-0.79) and time to CA-125 and HE4 nadir (>14 weeks, HR 0.37, 95% CI: 0.20-0.70 and >12 weeks, HR 0.43, 95% CI: 0.23-0.83) were prognostic factors of progression-free survival. More investigations on HE4 kinetics could help to better monitor patients with CA-125 concentration within normal values.
Language	English
Publishing date	2024-01-11
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2023.1308630
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Déficit de la recombinaison homologue dans les cancers épithéliaux de l’ovaire : de la caractérisation moléculaire au parcours des patientes.

Quesada, Stanislas / Solassol, Jérôme / Ray-Coquard, Isabelle / Fabbro, Michel

Bulletin du cancer

2023 Volume 110, Issue 4, Page(s) 371–381

Abstract: High-grade serous ovarian carcinoma (HGSOC), the most frequent and aggressive form of epithelial ovarian cancer is characterized in half of cases by homologous recombination deficiency (HRD). This molecular alteration is defined by distinct causes and ... ...

Title translation	Homologous recombination deficiency in epithelial ovarian cancers: from molecular characterization to patient journey.
Abstract	High-grade serous ovarian carcinoma (HGSOC), the most frequent and aggressive form of epithelial ovarian cancer is characterized in half of cases by homologous recombination deficiency (HRD). This molecular alteration is defined by distinct causes and consequences. The main and most characterized cause is the presence of an alteration affecting BRCA1 and BRCA2 genes. Regarding consequences, a specific genomic instability leads to increased sensitivity to platinum salts and poly (ADP-ribose) polymerase (PARPi) inhibitors. This latter point enabled the advent of PARPi in first and second line maintenance. As such, the initial and rapid evaluation of HRD status with molecular tests is a key step in the management of HGSOC. Until recently, the range of tests offered proved to be very limited and suffered from technical and medical limitations. This has recently led to the development and validation of alternatives, including academic ones. This "state of the art" review will bring a synthesis concerning the assessment of HRD status in HGSOCs. After a brief introduction of HRD (including main causes and consequences) and of its predictive value regarding PARPi, we will discuss the limitations of current molecular tests and the existing alternatives. Finally, we will contextualize this to the situation in France, with special consideration concerning the positioning and the financial coverage of these tests, with the perspective of optimizing patient management .
MeSH term(s)	Female ; Humans ; Carcinoma, Ovarian Epithelial/genetics ; Ovarian Neoplasms/pathology ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Genomic Instability ; Homologous Recombination
Chemical Substances	Poly(ADP-ribose) Polymerase Inhibitors
Language	French
Publishing date	2023-02-28
Publishing country	France
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	213270-9
ISSN	1769-6917 ; 0007-4551
ISSN (online)	1769-6917
ISSN	0007-4551
DOI	10.1016/j.bulcan.2023.02.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.15: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: PARP Inhibitor in Advanced Endometrial Carcinoma Beyond

Alexandre, Jérôme / Ray-Coquard, Isabelle / Joly, Florence

JCO precision oncology

2022 Volume 4, Page(s) 1025–1026

Language	English
Publishing date	2022-01-20
Publishing country	United States
Document type	Journal Article
ISSN	2473-4284
ISSN (online)	2473-4284
DOI	10.1200/PO.20.00177
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Molecular Mechanisms of Kaposi Sarcoma Development.

Karabajakian, Andy / Ray-Coquard, Isabelle / Blay, Jean-Yves

Cancers

2022 Volume 14, Issue 8

Abstract: Kaposi's sarcoma (KS) is a heterogeneous angioproliferative tumor that generally arises in the skin. At least four forms of this disease have been described, with the 'HIV'-related form being the most aggressive and can involve mucosae or visceral organs. ...

Abstract	Kaposi's sarcoma (KS) is a heterogeneous angioproliferative tumor that generally arises in the skin. At least four forms of this disease have been described, with the 'HIV'-related form being the most aggressive and can involve mucosae or visceral organs. Three quarters of KS cases occur in sub-Saharan Africa (SSA) as geographic variation is explained by the disparate prevalence of KS-associated herpes virus (KSHV), which is the underlying cause of this disease. It can infect endothelial and/or mesenchymal cells that consequently transdifferentiate to an intermediate state. KSHV establishes a latent phase in host cells in which latency proteins and various non-coding RNAs (ncRNAs) play a complex role in proliferation and angiogenesis. It also undergoes periods of sporadic lytic reactivation triggered by various biological signals in which lytic stage proteins modulate host cell signaling pathways and are key in KS progression. Complex interactions with the microenvironment with production of inflammatory cytokines with paracrine signaling is a standout feature of KS development and maintenance. KSHV impairs the immune response by various mechanisms such as the degradation of a variety of proteins involved in immune response or binding to cellular chemokines. Treatment options include classical chemotherapy, but other novel therapies are being investigated.
Language	English
Publishing date	2022-04-07
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers14081869
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito